Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
暂无分享,去创建一个
S. Vermeire | A. Gils | M. Ferrante | G. Van Assche | S. Tops | G. Compernolle | M. Bronswijk | A. Moens | M. Lenfant